AMGNAmgenFinished
Sotorasib and Panitumumab Versus Investigator's Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation
Colorectal Cancer (CRC)
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.9
3 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Worry score2
Score over time
- Stage
- Phase 3
- Patients
- 160 (final count)
- Started
- Apr 19, 2022
- Main results expected
- Jul 16, 2025
- Fully finished
- Apr 14, 2026
- Results posted
- Jul 22, 2026
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by BICR
Measured over: From randomization until DCO or death; median (min, max) time on trial was 6.23 (0.1, 14.0) months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- none yet
Trial ID NCT05198934 · record last updated 2026-07-22 · checked 2026-11-09 15:47 UTC